5 Undervalued Biotechnology & Medical Research Stocks for Thursday, October 26
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Thursday, October 26 based on AAII’s Stock Grades.Grace Malone
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Commentary & Analysis
4 Undervalued Biotechnology & Medical Research Stocks for Tuesday, August 01
Discover the top 4 undervalued Biotechnology & Medical Research stocks for Tuesday, August 01 based on AAII’s Stock Grades.Eunice Kim
Is Chemomab Therapeutics Ltd - ADR (CMMB) Stock a Good Investment?
Learn more about Chemomab Therapeutics Ltd - ADR's (CMMB) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | CMMB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $15.0 | $286.3 | 8% |
|
| Shares Out (Mil) | 7.8 | 54.2 | 17% |
|
| Institutional Ownership | 51.8% | 92.8% | 36% |
|
| Float (Mil) | 6.0 | 39.7 | 14% |
|
| Beta | 0.66 | 0.94 | 39% |
|
| Avg Daily Volume (000s) | 52 | 534 | 29% |
|
| Price Change (52-week) |
(44.4%) | 58.7% | 17% |
|
| Growth | CMMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (8.4%) | (10.1%) | 30% |
|
| EPS (5yr) | 16.5% | 16.0% | 61 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 21.9% | (15.6%) | 81% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | $0.000 | ($0.020) | ($0.030) | |
| Month Ago EPS | $0.000 | ($0.020) | ($0.030) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.000 | ($0.020) | ($0.030) | |
| Year/Year Chg | (100.0%) | (98.6%) | (97.2%) | |
| Financials | CMMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($9) | ($43) | 30% |
|
| EPS (TTM) | ($1.410) | ($1.400) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $-0 | $160 | 3% |
|
| Valuation | CMMB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.21 | 2.77 | 29% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CMMB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (50.0%) | (47.3%) | 12% |
|
| ROE | (61.3%) | (55.0%) | 13% |
|
| Liabilities to Assets | 10.7% | 29.6% | 6% |
|
| F-Score | 3 | 2 | 18% |
|
Chemomab Therapeutics Ltd. did not pass any screens on 8/20/2026.
